The crosstalk between Notch and MAPK pathway plays a role in MEK inhibitor resistance in
BRAF V600E metastatic melanoma (MM) and promotes migration in GNAQ Q209L uveal …

The discovery of activating BRAF mutations in approximately 50% of melanomas has led to
the development of MAPK pathway inhibitors, which have transformed melanoma therapy …

The role of Notch signaling in melanoma drug resistance is not well understood. In this
study, we show that although NOTCH proteins are upregulated in metastatic melanoma cell …

Melanoma is an aggressive disease with limited therapeutic options. Here, we determined
the effects of honokiol (HNK), a biphenolic natural compound on melanoma cells and …

Despite modern achievements in therapy of malignant melanomas new treatment strategies
are welcomed in clinics for survival of patients. Now it is supposed that personalized …

Activating mutations in Neuroblastoma RAS viral oncogene homolog (NRAS) are found in
15–30% of melanomas and are associated with a poor prognosis. Although MAP kinase …

Background BRAF-mutant melanoma patients benefit from the combinatorial treatments with
BRAF and MEK inhibitors. However, acquired drug resistance strongly limits the efficacy of …

The effects of Notch signaling are context-dependent and both oncogenic and tumor-
suppressive functions have been described. Notch signaling in melanoma is considered …

Most melanomas harbor oncogenic BRAFV600 mutations, which constitutively activate the
MAPK pathway. Although MAPK pathway inhibitors show clinical benefit in BRAFV600 …

Targeting the MAPK pathway by combined inhibition of BRAF and MEK has increased
overall survival in advanced BRAF-mutant melanoma in both therapeutic and adjuvant …